532999 Sigma-AldrichOrai1 Inhibitor, AnCoA4 - Calbiochem
AnCoA4 binds to the C-terminus region of Orai 1 and reduces its binding to STIM1 and blocks Ca2+ influx through the store operated calcium (SOC) channel (EC₅₀ = 880 nM).
More>> AnCoA4 binds to the C-terminus region of Orai 1 and reduces its binding to STIM1 and blocks Ca2+ influx through the store operated calcium (SOC) channel (EC₅₀ = 880 nM). Less<<Sinonimi: CRAC Inhibitor II
Prodotti consigliati
Panoramica
Replacement Information |
---|
Tabella delle specifiche principali
Empirical Formula |
---|
C₂₂H₁₈O₆ |
Prezzi e disponibilità
Numero di catalogo | Disponibilità | Confezionamento | Qtà/conf | Prezzo | Quantità | |
---|---|---|---|---|---|---|
5329990001 |
|
Bottiglia di vetro | 10 mg |
|
— |
References | |
---|---|
References | Sadaghiani, A.M., et al. 2014. Chem. Biol. 21, 1278. |
Product Information | |
---|---|
Form | Pale yellow solid |
Hill Formula | C₂₂H₁₈O₆ |
Chemical formula | C₂₂H₁₈O₆ |
Reversible | Y |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | Orail1 |
Purity | ≥96% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Numero di catalogo | GTIN |
5329990001 | 04055977282023 |
Documentation
Orai1 Inhibitor, AnCoA4 - Calbiochem MSDS
Titolo |
---|
Riferimenti bibliografici
Panoramica delle referenze |
---|
Sadaghiani, A.M., et al. 2014. Chem. Biol. 21, 1278. |
Brochure
Titolo |
---|
Neuroscience Solutions for productive research |
Informazioni tecniche
Titolo |
---|
Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System |
White Paper: Further considerations of antibody validation and usage. |